330 related articles for article (PubMed ID: 33833387)
1. Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape.
Hsieh YC; Kirschner K; Copland M
Leukemia; 2021 May; 35(5):1229-1242. PubMed ID: 33833387
[TBL] [Abstract][Full Text] [Related]
2. Treatment-free remission and immunity in chronic myeloid leukemia.
Ureshino H
Int J Hematol; 2021 May; 113(5):642-647. PubMed ID: 33651270
[TBL] [Abstract][Full Text] [Related]
3. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
Hughes A; Clarson J; Tang C; Vidovic L; White DL; Hughes TP; Yong AS
Blood; 2017 Mar; 129(9):1166-1176. PubMed ID: 28049640
[TBL] [Abstract][Full Text] [Related]
4. Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.
Hughes A; Yong ASM
Front Immunol; 2017; 8():469. PubMed ID: 28484463
[TBL] [Abstract][Full Text] [Related]
5. Role of cancer immunology in chronic myelogenous leukemia.
Ureshino H; Shindo T; Kimura S
Leuk Res; 2020 Jan; 88():106273. PubMed ID: 31765938
[TBL] [Abstract][Full Text] [Related]
6. Allelic polymorphisms of
Shindo T; Ureshino H; Kojima H; Tanaka H; Kimura S
Immunol Med; 2021 Jun; 44(2):61-68. PubMed ID: 32715973
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells.
Irani YD; Hughes A; Clarson J; Kok CH; Shanmuganathan N; White DL; Yeung DT; Ross DM; Hughes TP; Yong ASM
Br J Haematol; 2020 Nov; 191(3):433-441. PubMed ID: 32352166
[TBL] [Abstract][Full Text] [Related]
8. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
[TBL] [Abstract][Full Text] [Related]
9.
Ureshino H; Shindo T; Tanaka H; Saji H; Kimura S
Mol Cancer Ther; 2021 Jan; 20(1):142-149. PubMed ID: 33082274
[TBL] [Abstract][Full Text] [Related]
10. [Tyrosine kinase inhibitor therapy discontinuation for chronic myelogenous leukemia to achieve clinical cure: current status and future perspectives].
Kumagai T
Rinsho Ketsueki; 2018; 59(10):2094-2103. PubMed ID: 30305514
[TBL] [Abstract][Full Text] [Related]
11. [Chronic myeloid leukemia and NK cell immunity].
Ureshino H; Shindo T; Tanaka H; Kimura S
Rinsho Ketsueki; 2017; 58(4):381-388. PubMed ID: 28484170
[TBL] [Abstract][Full Text] [Related]
12. Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment.
Kong J; Qin YZ; Zhao XS; Hou Y; Liu KY; Huang XJ; Jiang H
Ann Hematol; 2021 Oct; 100(10):2557-2566. PubMed ID: 34278524
[TBL] [Abstract][Full Text] [Related]
13. Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia.
Irani YD; Kok CH; Clarson J; Shanmuganathan N; Branford S; Yeung DT; Ross DM; Hughes TP; Yong ASM
Blood Adv; 2023 Jun; 7(11):2364-2374. PubMed ID: 36622326
[TBL] [Abstract][Full Text] [Related]
14. The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation.
Xu Z; Yin J; Sun Q; Hu J; Hong M; Qian S; Liu W
Leuk Lymphoma; 2022 Nov; 63(11):2616-2626. PubMed ID: 35758278
[TBL] [Abstract][Full Text] [Related]
15. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
[No Abstract] [Full Text] [Related]
16. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
17. Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia.
Inselmann S; Wang Y; Saussele S; Fritz L; Schütz C; Huber M; Liebler S; Ernst T; Cai D; Botschek S; Brendel C; Calogero RA; Pavlinic D; Benes V; Liu ET; Neubauer A; Hochhaus A; Burchert A
Cancer Res; 2018 Nov; 78(21):6223-6234. PubMed ID: 30166420
[TBL] [Abstract][Full Text] [Related]
18. TKI discontinuation in CML: how do we make more patients eligible? How do we increase the chances of a successful treatment-free remission?
Hochhaus A; Ernst T
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):106-112. PubMed ID: 34889388
[TBL] [Abstract][Full Text] [Related]
19. [Analysis the influence factors of treatment free remission outcome with chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitors].
Zhao HF; Zhang Y; Dang LX; Liang JL; Chen SX; Guo Z; Li YL; Zu RR; Gui XD; Wei YP; Song Y
Zhonghua Yi Xue Za Zhi; 2022 May; 102(20):1523-1529. PubMed ID: 35692068
[No Abstract] [Full Text] [Related]
20. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D
Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
